(Q46865126)

25 December 2017

title

Effect of omalizumab on adenosine 5'-monophosphate responsiveness in subjects with allergic asthma (English)

1 reference

25 December 2017

1 reference

Prieto L

1

1 reference

25 December 2017

Gutiérrez V

2

1 reference

25 December 2017

Colás C

3

1 reference

25 December 2017

Tabar A

4

1 reference

25 December 2017

Pérez-Francés C

5

1 reference

25 December 2017

Bruno L

6

1 reference

25 December 2017

Uixera S

7

1 reference

25 December 2017

publication date

21 December 2005

1 reference

25 December 2017

International Archives of Allergy and Immunology

published in

1 reference

25 December 2017

volume

139

1 reference

25 December 2017

issue

2

1 reference

25 December 2017

page(s)

122-131

1 reference

25 December 2017

Bronchoconstriction induced by inhaled adenosine 5'-monophosphate in subjects with allergic rhinitis

cites work

1 reference

Relationship between airway sensitivity to adenosine 5' monophosphate and the shape of the concentration-response curve to methacholine in subjects with allergic rhinitis

21 January 2018

1 reference

Exhaled nitric oxide and bronchial responsiveness to adenosine 5'-monophosphate in subjects with allergic rhinitis

21 January 2018

1 reference

Comparative epidemiology of atopic and non-atopic wheeze and diagnosed asthma in a national sample of English adults

21 January 2018

1 reference

The role of allergy in the development of asthma

21 January 2018

1 reference

Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.

21 January 2018

1 reference

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

21 January 2018

1 reference

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

21 January 2018

1 reference

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

21 January 2018

1 reference

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

21 January 2018

1 reference

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

21 January 2018

1 reference

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

21 January 2018

1 reference

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.

21 January 2018

1 reference

Omalizumab-induced reductions in mast cell Fce psilon RI expression and function

21 January 2018

1 reference

Omalizumab treatment downregulates dendritic cell FcepsilonRI expression

21 January 2018

1 reference

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

21 January 2018

1 reference

Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.

21 January 2018

1 reference

Rapid effect of inhaled fluticasone propionate on airway responsiveness to adenosine 5'-monophosphate in mild asthma

21 January 2018

1 reference

Immunological and clinical changes in allergic asthmatics following treatment with omalizumab

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000090387

1 reference

25 December 2017

1 reference

25 December 2017